population
Organ Transplant Recipient
An organ transplant recipient is a person who has received a transplanted organ. The term describes a population rather than a single disease, symptom, or treatment outcome.
Find information tailored to the Organ Transplant Recipient population.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
May not suit people with this condition
Supplements and practices linked to problems for people with this condition.
ChagasupplementUnclear
Immune-stimulating constituents may oppose anti-rejection therapy. Clinical relevance is uncertain, but graft rejection is a high-consequence potential harm.
Open the Chaga pageTurkey TailsupplementUnclear
Turkey Tail may stimulate the immune system, which could increase the risk of transplant rejection in organ transplant recipients.
Open the Turkey Tail page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this conditionNothing in this library is currently recorded as helping with Organ Transplant Recipient. That means nothing is on file — not that nothing exists. Only 107 of 338 catalogued supplements have a written-up profile so far.
What to avoid
Interventions recorded as making it worse2 listedHighest probability
- →SupplementsChagaCertaintyLowSourceReference knowledge
Immune-stimulating constituents may oppose anti-rejection therapy. Clinical relevance is uncertain, but graft rejection is a high-consequence potential harm.
Open ChagaRationale
Chaga’s immune-stimulating beta-glucans may counteract immunosuppressive therapy and increase risk of graft rejection in organ transplant recipients.
- →SupplementsTurkey TailCertaintyLowSourceReference knowledge
Turkey Tail may stimulate the immune system, which could increase the risk of transplant rejection in organ transplant recipients.
Open Turkey TailRationale
Immune stimulation may increase the risk of transplant rejection by counteracting immunosuppressive therapy.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
An organ transplant recipient is a person who has received a transplanted organ. The term describes a population rather than a single disease, symptom, or treatment outcome. Information for this group is considered in the context of having undergone an organ transplant, and any medical condition should be discussed with a clinician.
Evidence-backed options
No evidence-backed options are listed for Organ Transplant Recipient in this reference. Because transplant care can involve individualized treatment considerations, any supplement or wellness option should be discussed with a clinician familiar with the person’s transplant history and current care.
What to avoid
After organ transplantation, immunosuppressive therapy is required to help prevent organ rejection. Supplements with immune-stimulating or immune-modulating activity may oppose that treatment. This concern applies to Astragalus, Reishi, Turkey Tail, Ashwagandha, Black Seed Oil, Lion's Mane, Melatonin, Panax Ginseng, Shilajit, Tongkat Ali (Eurycoma), American Ginseng, Black Elderberry, Cordyceps, Echinacea, Chaga, Glutathione, and Holy Basil (Tulsi). For some of these supplements, clinical safety in transplant recipients has not been established; for others, the potential harm is increased rejection risk.
Several products are flagged because they may change exposure to narrow-therapeutic-index anti-rejection medicines. CBD (Cannabidiol) can markedly and unpredictably increase exposure, with risks including nephrotoxicity, neurotoxicity, infection, or loss of immunosuppressive control after dose changes. St. John's Wort can reduce immunosuppressant levels and substantially increase rejection risk. Garlic, Coenzyme Q10, and Quercetin may also affect levels of medicines such as cyclosporine or tacrolimus, creating risks from toxicity or inadequate immunosuppression.
Saccharomyces Boulardii is flagged for a different reason: transplant recipients receiving immunosuppressive therapy have elevated risk of S. boulardii fungemia. Because rejection and medication-related toxicity can have serious consequences, these supplements warrant review with the transplant team before use, including when the concern is based on theoretical or preclinical effects.